| Valuation method | Value, £ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 5.00 | -98 |
| Intrinsic value (DCF) | 67.75 | -70 |
| Graham-Dodd Method | n/a | |
| Graham Formula | 6.20 | -97 |
Medistim ASA is a Norwegian medical technology company specializing in innovative devices for cardiovascular surgery. Founded in 1984 and headquartered in Oslo, Medistim develops, produces, and distributes advanced medical equipment, including the MiraQ Cardiac and MiraQ Vascular systems, which integrate ultrasound imaging and transit time flow measurement (TTFM) for precision in cardiac and vascular surgeries. The company also offers a range of flow probes, such as QuickFit TTFM and Vascular TTFM probes, designed to enhance surgical accuracy and outcomes. Medistim operates globally, serving markets in the U.S., Europe, and Asia, while also distributing third-party medical equipment. With a strong focus on intraoperative diagnostics, Medistim plays a critical role in improving surgical efficiency and patient care in the healthcare sector. The company's commitment to innovation and quality positions it as a key player in the medical equipment industry.
Medistim ASA presents a compelling investment opportunity due to its niche focus on high-precision cardiovascular surgical devices, a market with steady demand growth. The company's strong financials, including a net income of NOK 103.8 million and an EPS of 5.67, reflect profitability and operational efficiency. Additionally, Medistim's robust operating cash flow (NOK 143.1 million) and healthy cash reserves (NOK 179.2 million) provide financial stability. However, investors should consider the competitive nature of the medical device industry and potential regulatory risks. The company's beta of 1.017 suggests moderate market volatility, aligning with sector norms. A dividend yield of NOK 6 per share adds appeal for income-focused investors.
Medistim ASA holds a competitive edge through its specialized focus on intraoperative flow measurement and imaging technologies, which are critical in cardiovascular surgeries. The MiraQ systems' dual functionality (ultrasound + TTFM) differentiates Medistim from competitors who often offer these features separately. The company's global distribution network strengthens its market penetration, particularly in Europe and the U.S. However, Medistim operates in a highly competitive landscape dominated by larger players with broader product portfolios. Its reliance on cardiovascular surgery devices limits diversification compared to multi-segment medtech firms. The company's R&D focus on surgical precision and outcomes positions it well in value-based healthcare trends, but scaling against entrenched competitors remains a challenge. Medistim's financial health and profitability metrics are strong relative to its size, but it may face pricing pressures from larger rivals.